Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Cash from Financing Activities: 2017-2025

Historic Cash from Financing Activities for Rhythm Pharmaceuticals (RYTM) over the last 7 years, with Sep 2025 value amounting to $189.3 million.

  • Rhythm Pharmaceuticals' Cash from Financing Activities rose 7496.35% to $189.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $259.2 million, marking a year-over-year increase of 66.89%. This contributed to the annual value of $191.2 million for FY2024, which is 157.16% up from last year.
  • As of Q3 2025, Rhythm Pharmaceuticals' Cash from Financing Activities stood at $189.3 million, which was up 21,393.70% from -$889,000 recorded in Q2 2025.
  • Rhythm Pharmaceuticals' 5-year Cash from Financing Activities high stood at $189.3 million for Q3 2025, and its period low was -$965,000 during Q2 2023.
  • Moreover, its 3-year median value for Cash from Financing Activities was $4.2 million (2024), whereas its average is $44.2 million.
  • As far as peak fluctuations go, Rhythm Pharmaceuticals' Cash from Financing Activities skyrocketed by 38,293.22% in 2022, and later crashed by 133.33% in 2023.
  • Over the past 5 years, Rhythm Pharmaceuticals' Cash from Financing Activities (Quarterly) stood at $100,000 in 2021, then surged by 17,265.00% to $17.4 million in 2022, then crashed by 86.05% to $2.4 million in 2023, then spiked by 1,481.84% to $38.3 million in 2024, then surged by 7,496.35% to $189.3 million in 2025.
  • Its Cash from Financing Activities stands at $189.3 million for Q3 2025, versus -$889,000 for Q2 2025 and $32.5 million for Q1 2025.